Navigation Links
MicroConstants Expands Biomarker Testing and Analysis Services for Preclinical and Clinical Diagnostic Research
Date:6/25/2013

SAN DIEGO, June 25, 2013 /PRNewswire/ -- MicroConstants, a Contract Research Organization (CRO) specializing in regulated bioanalysis and DMPK, announces the appointment of Doinita Serban, Ph.D. as director of biomarker research to oversee the expansion of biomarker testing and analysis services for preclinical and clinical diagnostic research. Doinita's extensive experience with biomarker assay development, validation, and profiling of disease panels, coupled with the implementation of the Luminex platform, will enable MicroConstants to broaden their biomarker analysis capabilities to include additional assay formats, such as multiplex immunoassays, gene expression and profiling assays.

Doinita brings to MicroConstants more than 15 years of experience in the pharmaceutical industry specializing in cancer and vascular biology, immunology, and bioanalysis in preclinical and clinical research. She has spent over 10 years developing and validating biomarker assays for biopharmaceuticals on a variety of instrumentation platforms to support clinical diagnostic research for various therapeutic areas, including oncology, inflammation, infectious and vascular diseases.

"Although multiplex biomarker assays are a new service offering for MicroConstants, Doinita's in-depth knowledge of biomarker analysis and pharmacodynamic targets will be a valuable asset to the department as we expand our capabilities," says David F. Beyerlein, vice president of global operations at MicroConstants. "These biomarker assays will provide our pharmaceutical and biotech clients with valuable insight into the efficacy of therapies for cancer and other complex diseases to help guide their decisions throughout all phases of drug development."

There is an urgent need for the discovery of biomarkers that can be used in blood-based, non-invasive molecular tests. These tests can be used to assist in the detection and diagnosis of diseases, to classify tissues and patients for clinical trials, and to monitor disease response to treatment and relapse. Furthermore, linking the molecular aberrations of diseases to drug responses can guide treatment choices and identify new therapeutic applications.

MicroConstants will use the Luminex platform to study the cellular fitness of engineered cells in response to a collection of drugs, enabling the systematic analysis of thousands of gene-drug interactions and unveiling of resistance mechanisms. The multiplex technology will also be used to perform both gene and protein expression assays. Custom assays can be created for genotyping and protein assessment (i.e. tyrosine kinases, growth factors etc.), and commercially available kits can be used to monitor cytokine levels.

About MicroConstants, Inc.

MicroConstants is a GLP-compliant Contract Research Organization (CRO) focused on performing regulated bioanalysis, drug metabolism and pharmacokinetic analysis to support discovery, preclinical and clinical drug development studies. They specialize in method development, method validation and sample analysis of small molecules, biopharmaceuticals, biomarkers and metabolites using LC/MS/MS, HPLC/UV, immunoassay and multiplex techniques. For more information, please visit http://www.microconstants.com.


'/>"/>
SOURCE MicroConstants
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MicroConstants China Signs Site Management Organization Agreement with the Clinical Research Center of No. 307 Hospital
2. As Smartphone Usage Expands, Survey Says Nurses and Nursing Students Want Mobile Access to Credible Drug Data
3. BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility
4. RxAlly Expands National Network With Addition Of Nineteen Community Pharmacy Organizations Representing Over 2,000 Pharmacies
5. Clinical Interest in BioElectronics Products Expands to the Wound Care Market
6. S1 Biopharma Expands Focus to Include Male Sexual Health
7. PRA Expands Operations in Europe
8. USANA Health Sciences Expands Award-Winning Research and Development Team
9. Particle Sciences Expands its cGMP Capabilities with the Addition of Thin Films
10. Argus Expands Specialty Pharmacy with Amber Pharmacy Collaboration
11. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016  Sangamo BioSciences, ... therapeutic genome editing, announced that the U.S. Food ... Investigational New Drug (IND) application for SB-318, a ... therapy for Mucopolysaccharidosis Type I (MPS I). The ... Sangamo to initiate a Phase 1/2 clinical study ...
(Date:2/8/2016)... February 8, 2016 ... published by Allied Market Research titled, "World ... Forecasts, 2014-2020", estimates the world synthetic biology market ... and sequencing technology segment would continue to lead ... tools segment, collectively, held around half of the ...
(Date:2/8/2016)... HOUSTON , 8. Februar 2016 /PRNewswire/ ... veröffentlichte heute eine Infografik mit dem Titel ... ganzen Welt), mit der der Krankheit gegenüber ... die dazu ermutigen soll, Medikamentenresistenz bei Epilepsie ... der allgemeinen Diskussion zu machen. Mithilfe der ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Stephanie Hebert Insurance Agency, serving families ... new charity campaign. As part of their ongoing community involvement program, funds are ... that children deserve a voice, and in the spirit of neighbors helping neighbors ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... expansion into Canada to provide its range of unique and advantaged protective ... Quebec City that will provide bilingual customer service and marketing support. A new ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced today that nominations will be accepted February 8, 2016 through May ... , Awards include the Information Security Executive® of the Year, which recognizes ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially ... to make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, ...
(Date:2/8/2016)... , ... February 08, 2016 , ... The schedule ... in this country. The AutismOne 2016 Conference, which is being held May 25-29 at ... won’t hear elsewhere about helpful interventions and causes of chronic illness in children. , ...
Breaking Medicine News(10 mins):